

## CLINICAL DATA FEATURING APAS® TECHNOLOGY PRESENTED AT ECCMID

*ECCMID is the largest global conference for clinical microbiology, 23 - 26 April 2022*

**Adelaide, Australia, 27 April 2022:** Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT or the Company**), a leader in medical technology automation using artificial intelligence, is pleased to announce the presentation of data from five clinical studies featuring the APAS® Independence at the European Congress of Clinical Microbiology and Infectious Diseases (**ECCMID**), being held in Lisbon, Portugal from 23 - 26 April 2022.

### Key Points:

- **Presentation of data from five clinical studies featuring the APAS® Independence**
- **First published data demonstrating the use of APAS®-AMR for antimicrobial susceptibility testing**
- **Expanding clinical data presented from key regions: France, Germany, United Kingdom and United States**
- **APAS® Independence showcased on Clever Culture Systems booth**
- **In-person conference being held in Lisbon, Portugal from 23 – 26 April 2022**

The annual ECCMID conference is the leading conference for clinical microbiology and infectious diseases showcasing the latest innovative technologies from around the world. The 2022 ECCMID conference is being held in-person for the first time since 2019, and takes place in Lisbon, Portugal from 23 - 26 April 2022. The APAS® Independence is being showcased to delegates by LBT's wholly owned subsidiary, Clever Culture Systems (**CCS**), with the instrument on display at the CCS booth.

At this year's conference, there are three poster presentations and two platform oral presentations featuring the APAS® Independence being made by laboratories from France, Germany, United Kingdom and United States. This includes the first evaluation of the APAS® Independence made by a French laboratory and data presented from recent customer evaluations conducted in the United States and United Kingdom. The data presented provides valuable independent clinical evidence supporting the performance and utility of the APAS® Independence.

LBT CEO and Managing Director, Mr Brent Barnes said:

*"The ECCMID conference is the most prestigious conference in clinical microbiology held each year attended by global decision makers. The quality and quantity of data being presented featuring the APAS® Independence across the suite of analysis modules is world leading and further underlines our position as technology leaders in digital microbiology and the application of artificial intelligence in this field."*

### First publication featuring APAS®-AMR

The conference also features the first published data demonstrating the performance of the Company's APAS®-AMR technology for automated antimicrobial susceptibility testing (**AST**). The development of this analysis module has been funded under MTPConnect's Biomedical Translation Bridge program and is undergoing initial user evaluation by the Company's German Key Opinion Leader laboratory, Labor Dr Wisplinghoff.

The study compared the performance of the APAS® Independence versus manual plate reading by two experienced microbiologists at both 18-hours and 6-hours (for early reading, or Rapid-AST). The APAS® Independence demonstrated an overall agreement of 96.01% at 18-hours and 98.1% at 6-hours, highlighting the potential of the APAS® Independence for this new application.

LBT Scientific Director, Dr Steven Giglio said:

*"The performance of APAS®-AMR for standard and Rapid-AST has exceeded expectations. The importance of antimicrobial stewardship coupled with the need for faster identification of antimicrobial resistance to better address this global challenge makes APAS®-AMR an extremely compelling and unique offering to laboratories."*

## Presentation Details

All five posters presented at the conference will be made available on the Company website under the Scientific Library section once they become publicly available (<https://lbtinnovations.com/products/scientific-library/>).

### **Artificial intelligence (AI)-assisted antimicrobial susceptibility testing (AST): automated imaging and the use of artificial intelligence for interpretation of disc-diffusion AST according to EUCAST, including rapid antimicrobial susceptibility testing (RAST).**

*Nathalie Jazmati<sup>1, 2</sup>, Angela Nowag<sup>1, 2</sup>, Lena Radder<sup>1</sup>, Caroline Bernsen<sup>1</sup>, Rhys Hill<sup>3</sup>, Steven Giglio<sup>3</sup>, Hilmar Wisplinghoff<sup>1, 2</sup>*

*1. Wisplinghoff Laboratories - Cologne (Germany), 2. Institute for Medical Microbiology, Immunology and Hygiene, University Hospital of Cologne - Cologne (Germany), 3. LBT Innovations - Adelaide (Australia)*

### **Comparison of the APAS Independence Automated Plate Reader System with manual Standard-of-Care for processing urine culture specimens**

*Peiting Kuo<sup>1</sup>, Megan Chiu<sup>1</sup>, Phoebe Ramos<sup>1</sup>, Reuben Barba<sup>1</sup>, and David T. Pride<sup>1</sup>*

*1. University California San Diego (United States)*

### **Evaluation of the APAS Independence with Thermo Fisher Brilliance MRSA Analysis Module at NHS William Harvey Hospital**

*Benjamin Sloan<sup>1</sup>, Michael Dawson<sup>1</sup>, Rachel Arkley<sup>1</sup>*

*1. William Harvey Hospital - Kent (United Kingdom)*

### **Artificial Intelligence and Diagnostic Microbiology: Comparison the APAS Independence using Thermo Fisher UTI Brilliance Clarity Analysis Module with routine Plate-in-hand using CLED at NHS William Harvey Hospital.**

*Benjamin Sloan<sup>1</sup>, Michael Dawson<sup>1</sup>, Rachel Arkley<sup>1</sup>*

*1. William Harvey Hospital - Kent (United Kingdom)*

### **Streamlining urine processing with modular automation: a French experience with CPSE media**

*Jeanne-Marie Bidan<sup>1</sup>, Nathalie Rivoire<sup>1</sup>, Laurence Munier<sup>1</sup>, Claire Alcaraz<sup>1</sup>*

*1. Bio Med 21 - Dijon (France)*

Approved for release by the Chair of the LBT Board.

– ENDS –

## About LBT Innovations

LBT Innovations (LBT) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has a history of developing world leading products in microbiology automation. Its first product, MicroStreak®, was a global first in the automation of culture plate specimen processing. The Company's second product, the Automated Plate Assessment System (APAS® Independence) uses LBT's intelligent imaging and machine learning software to automate the imaging, analysis and interpretation of culture plates following incubation. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). Channel partners for the sale and distribution of the APAS® Independence are in place for the United States (Thermo Fisher Scientific, Inc; Exclusive Distributor) and Europe (Beckman Coulter, Inc; Marketing Agent).

## INVESTOR ENQUIRIES

<b>LBT Innovations</b>
<b>Brent Barnes</b> Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: <a href="mailto:info@lbtinnovations.com">info@lbtinnovations.com</a>